US Patent Issued to Takeda Pharmaceutical on Feb. 24 for "Substituted benzotriazinone metabolites of a GPR139 agonist" (California Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,465, issued on Feb. 24, was assigned to Takeda Pharmaceutical Co. Ltd. (Osaka, Japan).

"Substituted benzotriazinone metabolites of a GPR139 agonist" was invented by Stephen Uriah Bowlin (San Diego) and Amin Mohamed Kamel (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compounds that are mammalian metabolites of an agonist of G-protein-coupled receptor 1.39 (GPR139), intermediates used in the synthesis of such metabolites, pharmaceutical compositions comprising such metabolites, and the use of such metabolites as biomarkers and agents in the treatment of schizophrenia, for example, negative and/or cognitive symptoms of schizophrenia, disord...